3004
India's pharma industry shifts to high-value medicines
India's pharmaceutical industry is moving towards high-value medicines, complex chemistry, and advanced therapies while investing in domestic manufacturing to reduce reliance on imported active pharmaceutical ingredients (APIs).
India imported $4.35 billion worth of bulk drugs and APIs in FY25, with China accounting for 73.71% of the total. Government initiatives like the Production Linked Incentive (PLI) scheme have attracted ₹46,744 crore in committed investments by June 2026.
Source: Business Today



